According to its latest release, Isodiol (CSE: ISOL) (OTC: ISOLD) (FSE: LB6A.F) experienced significant growth during Fiscal Year 2018 with over $19,000,000 in sales since the acquisition of Iso International LLC in May 2017. The Fiscal Year ending March 31, 2017 showed audited revenues of $355,959 marking a year-over-year increase of 5276%, reported by the company.
Marco Aramont, CEO of Isodiol, said, “Isodiol has made significant strategic acquisitions over the last 12 months that are just now beginning to bear fruit, and the Company is well positioned as a global leader in the manufacturing, distribution, and full commercialization of hemp-derived CBD products.”
Laguna Blends acquired Iso International and subsequently changed its name to Isodiol as the umbrella company.
Iso International reported unaudited annualized sales of over $12,000,000 USD in 2017 revealing the reported 5,276% growth to be misleading in nature. HBJ estimates 55%-60% growth to be more accurate annual sales growth which can be attributed to Isodiol’s aggressive acquisition spree the last year.
The Company reported ‘significant acquisition advisory and consulting costs’ during Fiscal Year 2018 that the Company deemed necessary to accomplish the following transactions which have added to its bottom line.
- CN Pharma
- C3 Global Biosciences
- Bradley’s Biosciences
- Livecare Healthcare Inc.
- Kure Vapes
- BSPG Laboratories Ltd.
- Round Mountain Technologies LLC
As reported by the company in June, the previously announced transaction with BeTru Organics, Inc was canceled. The Company has agreed to continue contract manufacturing products for BeTru.